The schema newly classified 15.4% of persons without airflow obstruction as having COPD by minor diagnostic category, Surya P ...

Using imaging and respiratory symptoms, researchers identified up to 15.4% of individuals without airflow obstruction as ...

Explore the future of the COPD market with our comprehensive report covering 68 geographic markets. Forecast drug sales growth from $17.4B in 2023 to $42.2B by 2033, driven by the US market. Gain ...

As monsoon arrives, respiratory ailments tend to spike due to humidity, sudden weather shifts, and increased allergens. For ...

Current recommendations for diagnosis of COPD in patients with respiratory symptoms require detection of airflow obstruction ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...

The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater ...